NCT06619275View on ClinicalTrials.gov

Ripretinib (QINLOCK®) According to Current SmPC

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

October 17, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

November 30, 2027

Conditions
GIST - Gastrointestinal Stromal Tumor
Interventions
DRUG

Ripretinib

Switch-Control Tyrosine Kinase Inhibitor

Trial Locations (1)

Unknown

RECRUITING

Praxis für interdisziplinäre Onkologie und Hämatologie, Freiburg im Breisgau

Sponsors
All Listed Sponsors
collaborator

Deciphera Pharmaceuticals (Switzerland) AG

UNKNOWN

lead

iOMEDICO AG

INDUSTRY